IP Verse

Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins - EP2970980

The patent EP2970980 was granted to Janssen Biologics on Jul 27, 2022. The application was originally filed on Mar 7, 2014 under application number EP14768761A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2970980

JANSSEN BIOLOGICS
Application Number
EP14768761A
Filing Date
Mar 7, 2014
Status
Patent Maintained As Amended
Jun 24, 2022
Grant Date
Jul 27, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CABINET LAVOIXMay 15, 2019LAVOIX -

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS19920943852
DESCRIPTIONEP0218868
DESCRIPTIONEP0288088
DESCRIPTIONUS2004185047
DESCRIPTIONUS4376110
DESCRIPTIONUS5231024
DESCRIPTIONUS7250165
DESCRIPTIONUS7252823
DESCRIPTIONWO2013009648
DESCRIPTIONWO2014143184
DESCRIPTIONWO9102078
INTERNATIONAL-SEARCH-REPORTUS7070775
INTERNATIONAL-SEARCH-REPORTWO2009126564
INTERNATIONAL-SEARCH-REPORTWO2012147053
OPPOSITIONUS2012259095
OPPOSITIONUS6790444
OPPOSITIONUS7070775
OPPOSITIONWO2004085474
OPPOSITIONWO2006108455
OPPOSITIONWO2009126564
OPPOSITIONWO2013009648
SEARCHWO2013009648
SEARCHWO2014143184

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- JY PARK & J. JONGSTRA-BILEN, "Interactions between membrane IgM and the cytoskeleton involve the cytoplasmic domain of the immunoglobulin receptor", EUR. J. IMMUNOL., (199711), vol. 27, no. 11, pages 3001 - 3009
OPPOSITION- CAI et al., "C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo", Biotechnol. Bioeng., (20110000), vol. 108, no. 2, pages 404 - 412
OPPOSITION- DICK et al., "C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes", Biotechnol. Bioeng., (20080000), vol. 100, no. 6, pages 1132 - 1143
OPPOSITION- DINNIS et al., "Engineering Mammalian Cell Factories for Improved Recombinant Monoclonal Antibody Production: Lessons From Nature?", Biotechnol. Bioeng., (20050000), vol. 91, no. 2, pages 180 - 189
OPPOSITION- "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, (19980000), vol. 12, no. 1, pages 39 - 66
OPPOSITION- "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, (19980000), vol. 12, no. 1, pages 39 - 66, XP055592658
OPPOSITION- KIM et al., "Development of serum-free media for a recombinant CHO cell line producing recombinant antibody", Enzyme Microbiol. Technol., (20060000), vol. 39, no. 3, pages 426 - 433
OPPOSITION- LUO et al., "Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media", Biotechnol Bioeng, (20120000), vol. 109, no. 9, pages 2306 - 2315
OPPOSITION- RAJU T SHANTHA, "Terminal sugars of Fc glycans influence antibody effector functions of IgGs.", Current Opinion in Immunology, ELSEVIER, OXFORD., GB, GB , (20080801), vol. 20, no. 4, doi:10.1016/j.coi.2008.06.007, ISSN 0952-7915, pages 471 - 478
OPPOSITION- DINNIS et al., "Engineering Mammalian Cell Factories for Improved Recombinant Monoclonal Antibody Production: Lessons From Nature?", Biotechnol. Bioeng., (20050000), vol. 91, no. 2, pages 180 - 189, XP055592661
OPPOSITION- DICK et al., "C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes", Biotechnol. Bioeng., (20080000), vol. 100, no. 6, pages 1132 - 1143, XP055064805
OPPOSITION- CAI et al., "C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo", Biotechnol. Bioeng., (20110000), vol. 108, no. 2, pages 404 - 412, XP055129757
OPPOSITION- LUO et al., "Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media", Biotechnol Bioeng, (20120000), vol. 109, no. 9, pages 2306 - 2315, XP055064498
OPPOSITION- KIM et al., "Development of serum-free media for a recombinant CHO cell line producing recombinant antibody", Enzyme Microbiol. Technol., (20060000), vol. 39, no. 3, pages 426 - 433, XP005459377
SEARCH- JUN LUO ET AL, "Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media", BIOTECHNOLOGY AND BIOENGINEERING, (20120911), vol. 109, no. 9, doi:10.1002/bit.24510, ISSN 0006-3592, pages 2306 - 2315, XP055064498 [A] 1-15 * abstract * * page 2307, column l, paragraph 3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents